Flutensif 1,5 mg/5 mg modified - release tablets বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

flutensif 1,5 mg/5 mg modified - release tablets

les laboratoires servier - Инхибитори на калций и диуретици - 1,5 mg/5 mg modified - release tablets

Flutensif 1,5 mg/10 mg modified - release tablets বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

flutensif 1,5 mg/10 mg modified - release tablets

les laboratoires servier - Инхибитори на калций и диуретици - 1,5 mg/10 mg modified - release tablets

Natrixam 1,5 mg/5 mg modified - release tablets বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

natrixam 1,5 mg/5 mg modified - release tablets

les laboratories servier - Инхибитори на калций и диуретици - 1,5 mg/5 mg modified - release tablets

Natrixam 1,5 mg/10 mg modified - release tablets বুলগেরিয়া - বুলগেরিয় - Изпълнителна агенция по лекарствата

natrixam 1,5 mg/10 mg modified - release tablets

les laboratoires servier - Инхибитори на калций и диуретици - 1,5 mg/10 mg modified - release tablets

CALCIUM BOROGLUCONATE 20 % solutionh pro injectionibus 0.20 g/ml বুলগেরিয়া - বুলগেরিয় - БАБХ (Българска агенция по безопасност на храните)

calcium borogluconate 20 % solutionh pro injectionibus 0.20 g/ml

Ветпром АД - calcium borogluconate - инжекционен разтвор - 0.20 g/ml - биволи, говеда, кози, коне, котки, кучета, овце, свине

Verzenios ইউরোপীয় ইউনিয়ন - বুলগেরিয় - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - Неоплазми на гърдата - Антинеопластични средства - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.